Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GDTC

CytoMed Therapeutics Ltd

Feb 06 • 04:00PM ET

1.17

+0.09 8.33 %

Healthcare • Biotechnology • Singapore • NASD

Feb 05, 9:30 AMRenewed focus on recent clinical progress reaffirmation sparks premarket surge amid high volume trading.

Peers: NTLA FATE CRSP EDIT ADAP CELU BLUE CLLS PSTX SGMO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	65.58%	Shs Outstand	11.54M	Perf Week	45.05%
Market Cap	13.73M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.04M	Perf Month	-15.83%
Enterprise Value	11.93M	PEG	-	EPS next Q	-	Inst Own	0.05%	Short Float	0.66%	Perf Quarter	-44.55%
Income	-2.77M	P/S	80.76	EPS this Y	-	Inst Trans	-31.87%	Short Ratio	0.05	Perf Half Y	-37.10%
Sales	0.17M	P/B	2.41	EPS next Y	-	ROA	-37.94%	Short Interest	0.03M	Perf YTD	-12.36%
Book/sh	0.49	P/C	6.13	EPS next 5Y	-	ROE	-42.29%	52W High	3.68 -68.21%	Perf Year	-59.38%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	-588.52% -290.76%	ROIC	-46.59%	52W Low	0.73 60.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.56% 15.09%	Perf 5Y	-
Dividend TTM	-	EV/Sales	70.18	EPS Y/Y TTM	-21.99%	Oper. Margin	-1740.21%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.81	Sales Y/Y TTM	-	Profit Margin	-1629.00%	RSI (14)	54.56	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.81	EPS Q/Q	-109.86%	SMA20	18.99%	Beta	-0.45	Target Price	5.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	-13.24%	Rel Volume	1.30	Prev Close	1.08
Employees	43	LT Debt/Eq	0.06	Earnings	-	SMA200	-38.66%	Avg Volume	590.32K	Price	1.17
IPO	Apr 14, 2023	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	768,133	Change	8.33%

Jan-29-26 10:11AM	Cytomed Therapeutics refutes misleading claims, reaffirms clinical progress (TipRanks)
Jan-28-26 10:00AM	CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress (GlobeNewswire)
Jan-13-26 08:00AM	CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital (GlobeNewswire)
Dec-08-25 08:00AM	CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia (GlobeNewswire)
Nov-18-25 08:00AM	CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India (GlobeNewswire)
08:00AM	Loading…
Nov-06-25 08:00AM	CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy (GlobeNewswire)
Oct-22-25 08:00AM	CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% (GlobeNewswire)
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
Oct-14-25 08:00AM	CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets (GlobeNewswire) +16.58%
Oct-02-25 07:00AM	CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic ?d T Cells in Acute Myeloid Leukemia (GlobeNewswire)
Aug-28-25 09:00AM	Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition (GlobeNewswire)
Aug-18-25 09:00PM	CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program (GlobeNewswire)
Jul-21-25 10:01AM	Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies (GlobeNewswire)
Apr-28-25 04:05PM	CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) +5.70%
Feb-06-25 07:20AM	CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders (GlobeNewswire)
07:58AM	Loading…
Jan-07-25 07:58AM	CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India (TipRanks) -13.70%
06:45AM	CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India (Clinical Trials Arena)
Jan-06-25 07:00AM	CytoMed Therapeutics signs Business and Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India (GlobeNewswire)
07:00AM	CytoMed Therapeutics signs Business & Research Collaboration Agreement with Indias SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India (GlobeNewswire)
Nov-20-24 07:00AM	Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies (GlobeNewswire) +9.99%
Oct-07-24 07:00AM	CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant (GlobeNewswire) +10.04%
Oct-04-24 07:27AM	CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine (TipRanks) +7.94%
Oct-03-24 07:00AM	CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank (GlobeNewswire)
Sep-30-24 07:00AM	CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire) -8.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire) +14.29%
07:00AM	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (?d) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
07:00AM	Loading…
07:00AM	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta ( ) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Mar-20-24 08:30AM	CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration (ACCESSWIRE) -5.60%
Mar-18-24 06:00AM	CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies (GlobeNewswire) +5.63%
Mar-04-24 05:00AM	CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair (GlobeNewswire)
Jan-29-24 07:00AM	Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (GlobeNewswire)
Dec-05-23 07:30AM	CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology (PR Newswire)
Nov-17-23 09:21AM	CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update (PR Newswire) -8.60%
Nov-14-23 07:47AM	CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (PR Newswire)
Oct-24-23 01:00PM	CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology (ACCESSWIRE) +5.04%
Sep-25-23 07:00AM	Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology (PR Newswire) +6.45%
Aug-29-23 09:00AM	CytoMed Expands Research Collaboration into China After Entering Into MOU (ACCESSWIRE)
Aug-17-23 07:30AM	CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit (Newsfile)
Aug-15-23 01:00PM	CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR T In Vivo Persistency (PR Newswire)
Aug-01-23 07:00AM	Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (PR Newswire)
Jul-27-23 09:00AM	CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology (ACCESSWIRE)
Jul-14-23 10:52AM	Insiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51m (Simply Wall St.)
Jul-06-23 07:00AM	A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US (PR Newswire) +6.23%
Jun-28-23 09:00AM	CytoMed Therapeutics Collaborates With Cancer Treatment Center to Advance Its Unique CAR-T Technology (NewMediaWire) +7.02%
May-11-23 09:00AM	CytoMed Therapeutics to Ring Nasdaq Closing Bell (PR Newswire) -6.31%
May-09-23 10:07AM	CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology (PR Newswire) -19.50%
Apr-13-23 08:00PM	CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering (PR Newswire)

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
mDR Ltd	10% Owner	Sep 23 '25	Proposed Sale	1.88	54,644	102,731	Sep 22 01:34 PM
mDR Ltd	10% Owner	Jun 23 '25	Proposed Sale	2.10	81,482	171,112	Jun 23 07:25 AM
mDR Ltd	10% Owner	Mar 24 '25	Proposed Sale	2.66	86,410	229,850	Mar 24 12:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GDTC

CytoMed Therapeutics Ltd

Upgrade your FINVIZ experience